- Home
- MGN vs PLUR Comparison
MGN vs PLUR Comparison
Compare MGN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | PLUR |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 33.9M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | MGN | PLUR |
|---|---|---|
| Price | $0.17 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.4M | 5.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $0.13 | $2.82 |
| 52 Week High | $5.18 | $5.96 |
Technical Indicators
Market Signals| Indicator | MGN | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 54.85 |
| Support Level | $0.13 | $3.20 |
| Resistance Level | $0.36 | $3.90 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 37.38 | 57.45 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.